Skip links

Tzield® (teplizumab-mzwv)

Full Name Tzield® (teplizumab-mzwv)
Drug Tzield
Manufacturer Sanofi
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D
Disease Type 1 Diabetes (T1D)
Therapeutic Area Endocrinology & Bone Specialty
Enrollment Form Link Tzield Enrollment Form
Phone Number 800-670-5321
Fax Number 877-655-4364
Product Website